Cite

Number of patients reporting adverse events

O Fexo (n = 22)O Levo (n = 25)L Fexo (n = 22)P
Sleepiness816120.15
Dizziness3830.21
Nausea1230.52
Dyspepsia3560.48
Fatigue4660.72
Rash1230.52

Demographic data of the patient participants by treatment group

Original fexofenadine (n = 22)Original levocetirizine (n = 25)Locally-manufactured fexofenadine (n = 22)
Age (years)32.3 ± 9.332.6 ± 11.337.6 ± 12.2
Female (%)697268
Duration (years)8.2 ± 7.67.3 ± 6.37.0 ± 6.5
Mild (%)777259
Moderate to severe (%)232841

Baseline, post-treatment, and improvement in total symptom score, disease-specific quality of life, PNIF, allergen-induced wheal and flare size

O Fexo (n = 22)O Levo (n = 25)L Fexo (n = 22)Comparison three groups (P)O Fexo versus O Levo (P)O Fexo versus L Fexo (P)O Levo versus L Fexo (P)
Total symptom score (mean (95% CI))
Baseline9.50 (7.19,11.81)10.80 (9.37,12.23)10.18 (7.99,12.37)0.621.001.001.00
Post-treatment5.05 (3.42,6.67)5.28 (4.21,6.35)5.86 (4.83,6.90)0.631.001.001.00
Change4.45 (2.51,6.40)5.52 (3.98,7.06)4.32 (2.43,6.21)0.551.001.000.96
Nonotolaryngic symptoms (mean (95% CI))
Baseline13.77 (9.74,17.81)12.88 (10.20,15.56)12.27 (9.65,14.89)0.791.001.001.00
Post-treatment7.59 (4.09,11.09)5.68 (3.82,7.54)6.95 (4.17,9.74)0.571.000.911.00
Change6.18 (3.44,8.92)7.20 (4.41,9.99)5.32 (2.82,7.82)0.591.001.000.92
Work and study performance (mean (95% CI))
Baseline1.86 (1.01,2.72)2.60 (1.53,3.67)1.91 (1.20,2.62)0.400.711.000.80
Post-treatment0.91 (0.24,1.58)1.00 (0.29,1.71)0.91 (0.42,1.40)0.971.001.001.00
Change0.95 (0.34,1.57)1.60 (0.55,2.65)1.00 (0.42,1.58)0.420.731.000.84
Exertion (mean (95% CI))
Baseline2.55 (1.51,3.59)2.04 (0.92,3.16)2.36 (1.37,3.36)0.771.001.001.00
Post-treatment1.23 (0.44,2.01)0.88 (0.18,1.58)1.45 (0.57,2.34)0.551.001.000.85
Change1.32 (0.50,2.13)1.16 (0.42,1.90)0.91 (0.24,2.06)0.811.001.001.00
Sleep disturbance (mean (95% CI))
Baseline3.59 (2.23,4.95)4.04 (2.86,5.22)4.36 (2.99,5.74)0.691.001.001.00
Post-treatment1.55 (0.84,2.25)1.76 (0.73,2.79)1.73 (0.85,2.61)0.931.001.001.00
Change2.05 (1.04,3.06)2.28 (1.12,3.44)2.64 (1.42,3.85)0.761.001.001.00
Social disturbance (mean (95% CI))
Baseline1.82 (0.73,2.91)2.80 (1.62,3.98)2.68 (1.45,3.92)0.420.660.891.00
Post-treatment1.14 (0.37,1.90)1.52 (0.57,2.47)0.86 (0.28,1.45)0.481.001.000.69
Change1.82 (0.83,2.80)1.28 (0.39,2.17)1.82 (0.83,2.80)0.160.881.171.00
Emotional disturbance (mean(95%CI))
Baseline6.41 (4.15,8.67)7.88 (5.63,10.13)8.14 (5.58,10.70)0.521.000.891.00
Post-treatment2.77 (1.56,3.98)3.60 (2.05,5.15)3.23 (1.85,4.60)0.691.001.001.00
Change3.64 (1.92,5.35)4.28 (2.17,6.39)4.91 (2.80,7.02)0.661.001.001.00
Overall general health (mean (95% CI))
Baseline2.14 (1.77,2.51)2.08 (1.74,2.42)1.77 (1.41,2.13)0.291.000.440.61
Post-treatment2.50 (2.17,2.83)2.68 (2.42,2.94)2.14 (1.89,2.38)0.021.000.200.02
Change0.36 (–0.01,0.74)0.60 (0.22,0.98)0.36 (0.01,0.71)0.551.001.001.00
PNIF (L/min) (mean (95% CI))
Baseline93.86 (79.06,108.66)92.71 (80.70,104.72)92.27 (78.85,105.69)0.981.001.001.00
Post-treatment93.86 (75.23,112.50)92.20 (81.51,102.89)90.91 (78.68,103.14)0.961.001.001.00
Change0 (–9.25,9.25) (17.74,28.35)3.20 (–11.84,18.24) (20.60,28.04)–1.36 (–11.23,8.51) (18.05,28.68)0.851.001.001.00
Change–12.27 (–19.05,-5.49)–13.52 (–18.61, –8.43)–14.09 (–19.95, –8.23)0.901.001.001.00
Wheal size (mm) (mean (95% CI))
Baseline11.36 (9.44,13.29)14.04 (11.64,16.44)14.00 (9.56,18.44)0.290.680.421.00
Post-treatment8.91 (7.04,10.78)10.24 (8.52,11.96)9.77 (7.36,12.18)0.611.000.991.00
Change–2.45 (–4.56, –0.55)–1.24 (–6.50, –1.98)–4.23 (–6.95, –1.51)0.440.830.771.00
Flare size (mm) (mean (95% CI))
Baseline35.32 (29.94,40.69)38.58 (33.11,44.05)37.45 (28.79,46.12)0.841.001.001.00
Post-treatment23.05 (17.74,28.35)24.32 (20.60,28.04)23.36 (18.05,28.68)0.921.001.001.00
Change–12.27 (–19.05,-5.49)–13.52 (–18.61, –8.43)–14.09 (–19.95, –8.23)0.901.001.001.00
eISSN:
1875-855X
Language:
English
Publication timeframe:
6 times per year
Journal Subjects:
Medicine, Assistive Professions, Nursing, Basic Medical Science, other, Clinical Medicine